Sarah Sunshine, MD

Articles by Sarah Sunshine, MD

Multidisciplinary Collaboration for Identifying and Managing ADC-Related Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

February 3rd 2026

Oncology care thrives on teamwork, emphasizing patient education and communication to manage treatment-related ocular toxicities effectively.

Variability in Prophylactic Strategies and Use of Supportive Care Across ADCs

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 27th 2026

Explore the differences in supportive care for antibody-drug conjugates and their impact on ocular health in patients.

Differentiating Urgent vs. Non-Urgent Ocular AEs in ADC-Treated Patients

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 27th 2026

Experts discuss the importance of monitoring ocular toxicities in cancer treatment, emphasizing timely interventions and effective communication between oncologists and ophthalmologists.

Aligning Clinical Trial Findings With Real-World Ocular Toxicity Outcomes with ADCs in Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 20th 2026

Experts discuss the alignment of clinical trial data with real-world experiences in managing ocular toxicities in cancer treatments.

Defining the Roles of Ophthalmologists and Optometrists in Managing ADC-Related Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 20th 2026

Explore the roles of optometrists and ophthalmologists in managing ocular toxicities, ensuring timely patient care and effective treatment strategies.

Best Practices for Discussing and Managing Ocular Surface Toxicities When Using ADCs for Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 13th 2026

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

Managing ADC Dose Adjustments to Improve Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 13th 2026

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

Ocular Toxicities Across Breast, Lung, and Gynecologic ADCs: Incidence, Management, and Clinical Implications

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 6th 2026

Explore the latest insights on antibody-drug conjugates in oncology and their associated ocular toxicities, enhancing patient care and treatment outcomes.

Managing Ocular Symptoms and Comorbidities with ADC Use: When to Involve Ophthalmologists

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 6th 2026

Medical oncologists explore the importance of ophthalmology referrals for ocular toxicities, emphasizing collaboration for optimal patient care.

Defining Grade 1 Ocular Toxicities and When to Prioritize Baseline Eye Exams While Using ADCs

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 22nd 2025

Ophthalmologists discuss the importance of grading dry eye symptoms and the necessity of eye exams before starting certain treatments.

Strengthening Oncology–Ophthalmology Communication for Management of ADC Associated Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 22nd 2025

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 16th 2025

Ocular toxicities from cancer treatments present complexities; understanding symptoms and timely ophthalmology involvement is crucial for effective management.

Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 16th 2025

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

Sarah Sunshine, MD

Articles by Sarah Sunshine, MD

Multidisciplinary Collaboration for Identifying and Managing ADC-Related Ocular Toxicities

Variability in Prophylactic Strategies and Use of Supportive Care Across ADCs

Differentiating Urgent vs. Non-Urgent Ocular AEs in ADC-Treated Patients

Aligning Clinical Trial Findings With Real-World Ocular Toxicity Outcomes with ADCs in Solid Tumors

Defining the Roles of Ophthalmologists and Optometrists in Managing ADC-Related Ocular Toxicities

Best Practices for Discussing and Managing Ocular Surface Toxicities When Using ADCs for Solid Tumors

Managing ADC Dose Adjustments to Improve Ocular Toxicities

Ocular Toxicities Across Breast, Lung, and Gynecologic ADCs: Incidence, Management, and Clinical Implications

Managing Ocular Symptoms and Comorbidities with ADC Use: When to Involve Ophthalmologists

Defining Grade 1 Ocular Toxicities and When to Prioritize Baseline Eye Exams While Using ADCs

Strengthening Oncology–Ophthalmology Communication for Management of ADC Associated Ocular Toxicities

Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies